Study of N-Acetylcysteine in Acute Liver Failure (ALF)

Phase 4 Terminated 255 enrolled University of Texas Southwestern Medical Center National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with acute liver failure.

Timeline

Start: 2008-12
Primary completion: 2015-10-15
Completion: 2016-03

Publications

Stravitz RT, Fontana RJ, Karvellas C, Durkalski V, McGuire B, Rule JA, Tujios S, Lee WM; Acute Liver Failure Study Group. Future directions in acute liver failure. Hepatology. 2023 Oct 1;78(4):1266-1289. doi: 10.1097/HEP.0000000000000458. Epub 2023 May 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	N-acetylcysteine	Small molecule	150 mg/kg	Intravenous

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

Summary

Timeline

Publications

Drugs

Indications